Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Neoplasms: early-phase trial registry
1 of 5 indexed Prostate Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Prostate Neoplasms: 5 US clinical trials tracked, 1 recruiting.
Prostate Neoplasms is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition prostate-neoplasms
OPEN 1 | RECR 20% | LATE 0 | EARLY 4 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Prostate Neoplasms lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Neoplasms is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Prostate Neoplasms research.
National Cancer Institute (NCI) accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Prostate Neoplasms trials plan to enrol fewer than 100 people.
Median target enrolment is 86 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Prostate Neoplasms research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Cancer Institute (NCI)
NCT04633252
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT03173924
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Accuray Incorporated
NCT00643617
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Cancer Institute (NCI)
NCT02649855
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Baylor College of Medicine
NCT00425503
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Neoplasms page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Prostate Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Prostate Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Neoplasms condition card totals 5 registered trials; most-linked intervention Docetaxel; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.